Non-small-cell lung cancer — a high-incidence, often high-TMB setting for neoantigen vaccines combined with checkpoint blockade.
CancerNetwork discusses the potential for personalized cancer vaccines to transform kidney cancer treatment options. This commentary reflects growing industry interest in expanding neoantigen vaccine indications beyond melanoma and lung cancer into other solid tumor types with unmet needs.
Fred Hutchinson Cancer Center has launched a Phase I trial recruiting patients with stage IIIC-IV melanoma, metastatic breast cancer, or stage III-IV NSCLC. The study evaluates a personalized neo-antigen peptide vaccine combined with the Th1-polarizing adjuvant poly ICLC to induce polyclonal cytolytic T cell immunity.
David Braun, MD, discusses a Phase 2 trial of an individualized neoantigen therapy for renal cell carcinoma (RCC). This coverage signals ongoing clinical validation of personalized approaches in urologic malignancies beyond melanoma and lung cancer.
UNC Lineberger Comprehensive Cancer Center has suspended a Phase I trial of the PANDA-VAC personalized neoantigen peptide vaccine administered concurrently with pembrolizumab. The study was designed for advanced squamous NSCLC and head and neck squamous cell carcinoma, assessing safety and dose adjustment protocols.
A study identifies L3EMP, a microprotein encoded by LINC00973, as a driver of lung adenocarcinoma progression via SIRT1 stabilization. The research highlights L3EMP as a potential neoantigen target, evaluating its immunotherapeutic potential using synthetic peptides and CAR-T cells.
Frontiers published findings on using RNA sequencing to enable neoantigen discovery and vaccine validation in breast and lung cancer. This work highlights the role of transcriptomic data in identifying high-quality neoantigens and validating their presence in tumor samples, a critical step for ensuring vaccine relevance.